Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex enters significant long-term contract with Sepracor

Cyprotex PLC (LSE:CRX), the drug discovery technology and information company, is pleased to announce that it has entered into a significant long-term contract for Cyprotex's integrated Cloe offering with the major US-based pharmaceutical company, Sepracor Inc.

Commenting on the agreement, Robert Morrisson Atwater, Chief Executive Officer of Cyprotex PLC, said: "This is Cyprotex's first major US partnership which shows that our technologies, expertise and general approach are attracting a wider audience. This deal is clear demonstration that Cyprotex is gaining well deserved recognition as a valuable partner in drug discovery."

For further information:

Cyprotex PLC
Robert Morrisson Atwater, Chief Executive Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Media Enquires:

Abchurch Communications
Heather Salmond / Samantha Robbins
Tel: +44 (0) 20 7398 7700
samantha.robbins@abchurch-group.com
www.abchurch-group.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close